Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Grace Friel is active.

Publication


Featured researches published by Grace Friel.


British Journal of Cancer | 2016

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium

Rikki Cannioto; Michael J. LaMonte; Linda E. Kelemen; Harvey A. Risch; Kevin H. Eng; Albina N. Minlikeeva; Chi-Chen Hong; J. Brian Szender; Lara E. Sucheston-Campbell; Janine M. Joseph; Andrew Berchuck; Jenny Chang-Claude; Daniel W. Cramer; Anna deFazio; Brenda Diergaarde; Thilo Dörk; Jennifer A. Doherty; Robert P. Edwards; Brooke L. Fridley; Grace Friel; Ellen L. Goode; Marc T. Goodman; Peter Hillemanns; Estrid Høgdall; Satoyo Hosono; Joseph L. Kelley; Susanne K. Kjaer; Rüdiger Klapdor; Keitaro Matsuo; Kunle Odunsi

Background:Little is known about modifiable behaviours that may be associated with epithelial ovarian cancer (EOC) survival. We conducted a pooled analysis of 12 studies from the Ovarian Cancer Association Consortium to investigate the association between pre-diagnostic physical inactivity and mortality.Methods:Participants included 6806 women with a primary diagnosis of invasive EOC. In accordance with the Physical Activity Guidelines for Americans, women reporting no regular, weekly recreational physical activity were classified as inactive. We utilised Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) representing the associations of inactivity with mortality censored at 5 years.Results:In multivariate analysis, inactive women had significantly higher mortality risks, with (HR=1.34, 95% CI: 1.18–1.52) and without (HR=1.22, 95% CI: 1.12–1.33) further adjustment for residual disease, respectively.Conclusion:In this large pooled analysis, lack of recreational physical activity was associated with increased mortality among women with invasive EOC.


Journal of Lower Genital Tract Disease | 2015

Aspirin and Acetaminophen Use and the Risk of Cervical Cancer.

Grace Friel; Cici S. Liu; Nonna Kolomeyevskaya; Shalaka S. Hampras; Bridget Kruszka; Kristina Schmitt; Rikki Cannioto; Shashikant Lele; Kunle Odunsi; Kirsten B. Moysich

Objective In this study, we investigated whether regular use of aspirin or acetaminophen was associated with risk of cervical cancer in women treated at an American cancer hospital. Methods This case-control study included 328 patients with cervical cancer and 1,312 controls matched on age and decade enrolled. Controls were women suspected of having but not ultimately diagnosed with a neoplasm. Analgesic use was defined as regular (at least once per week for ≥6 months), frequent (≥7 tablets/week), very long term (≥11 years), or frequent, long term (≥7 tablets per week for ≥5 years). Results Compared to nonusers, frequent aspirin use was associated with decreased odds of cervical cancer (odds ratio, 0.53; 95% confidence interval, 0.29-0.97). A slightly larger association was observed with frequent, long-term use of aspirin (odds ratio, 0.46; 95% confidence interval, 0.22-0.95). Acetaminophen use was not associated with the risk of cervical cancer. Conclusions Our findings suggest that frequent and frequent, long-term use of aspirin is associated with decreased odds of cervical cancer. To our knowledge, this is the first US-based study examining these associations. Given the widespread use of nonsteroidal anti-inflammatory drugs and acetaminophen worldwide, further investigations of the possible role of analgesics in cervical cancer, using a larger sample size with better-defined dosing regimens, are warranted.


Cancer Causes & Control | 2017

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium

Albina N. Minlikeeva; Jo L. Freudenheim; Rikki Cannioto; J. Brian Szender; Kevin H. Eng; Francesmary Modugno; Roberta B. Ness; Michael J. LaMonte; Grace Friel; Brahm H. Segal; Kunle Odunsi; P.C. Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E. Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J. Jordan; Christina M. Nagle; Harvey A. Risch; Mary Anne Rossing; Jennifer A. Doherty; Marc T. Goodman; Robert P. Edwards; Keitaro Matsuo; Mika Mizuno

PurposeSurvival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.MethodsUsing pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.ResultsHistory of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01–1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88–1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87–1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35–0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03–1.40, HR = 1.28; 95% CI = 1.05–1.55, and HR = 1.63; 95% CI = 1.20–2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53–0.94.ConclusionsHistories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.


Cancer Epidemiology, Biomarkers & Prevention | 2015

Use of common analgesics is not associated with ovarian cancer survival

Albina N. Minlikeeva; Jo L. Freudenheim; Wei-Hsuan Lo-Ciganic; Kevin H. Eng; Grace Friel; Brenda Diergaarde; Francesmary Modugno; Rikki Cannioto; Emily H. Gower; J. Brian Szender; K.S. Grzankowski; Kunle Odunsi; Roberta B. Ness; Kirsten B. Moysich

Background: Use of analgesics has been associated with lower risk of ovarian cancer, but, to date, very few studies have explored the association between analgesics and ovarian cancer survival. Methods: We examined the relationship between self-reported prediagnostic use of aspirin, ibuprofen, and acetaminophen and overall survival (OS), progression-free survival (PFS), ascites at the time of primary treatment, and persistence of disease after primary treatment among 699 women diagnosed with epithelial ovarian carcinoma. The associations between use of these medications and OS and PFS were estimated using Cox proportional hazards models. We utilized unconditional logistic regression models to estimate associations between medication use and presence of ascites and persistence of disease. Results: Prediagnostic intake of aspirin, both low-dose and regular-dose, ibuprofen, and acetaminophen was not associated with any of the outcomes of interest. Conclusions: Our results indicate a lack of association between prediagnostic intake of selected analgesics and OS, PFS, presence of ascites at the time of primary treatment, and persistence of disease after primary treatment. Impact: Prediagnostic intake of analgesics may not be associated with ovarian cancer outcomes. Cancer Epidemiol Biomarkers Prev; 24(8); 1291–4. ©2015 AACR.


International Journal of Gynecological Cancer | 2015

Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.

Nonna Kolomeyevskaya; J.B. Szender; Gary Zirpoli; Albina N. Minlikeeva; Grace Friel; Rikki Cannioto; R. Brightwell; K.S. Grzankowski; Kirsten B. Moysich

Objectives Prognostic risk factors influencing survival in patients with epithelial ovarian cancer (EOC) include tumor stage, grade, histologic subtype, debulking, and platinum status. Little is known about the impact of hormonal milieu and reproductive factors before cancer diagnosis on clinical outcome. We sought to evaluate whether oral contraceptive (OC) use carries any prognostic significance on overall survival (OS) in patients with EOC. Methods Newly diagnosed patients with EOC, fallopian tube, and primary peritoneal cancers between 1982 and 1998 were prospectively evaluated with a comprehensive epidemiologic questionnaire. A retrospective chart review was performed to abstract clinicopathologic data, including OS. A Kaplan-Meier analysis was performed to compare survival across various exposures. A Cox regression model was used to compute adjusted hazards ratios (aHRs) and 95% confidence intervals (CIs). Results We identified 387 newly diagnosed cancers with evaluable information in this cohort. Decreased risk of death was observed in women who reported prior use of OC (aHR, 0.79; 95% CI, 0.58–1.09), previous pregnancy (aHR, 0.77; 95% CI, 0.57–1.04), or a live birth (aHR, 0.81; 95% CI, 0.60–1.08) after adjusting for age at diagnosis, stage, and histologic subtype. Oral contraceptive use was associated with a crude reduced risk of death (HR, 0.55; 95% CI, 0.42–0.72), with reported median OS of 81 months in OC users versus 46 months in nonusers. Patients who reported a single live birth experienced the largest potential survival advantage (aHR, 0.61; 95% CI, 0.39–0.94). Oral contraceptive use and prior pregnancy were associated with improved survival across all strata. Conclusions Oral contraceptive use may have lasting effects on epithelial ovarian tumor characteristics conferring favorable prognosis. Putative mechanisms that affect tumor biology include complex interactions between ovarian cells, host immune cells, and hormonal microenvironment during carcinogenesis. Future efforts should be directed to determine the role of reproductive factors in antitumor immunity.


British Journal of Cancer | 2017

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report

Albina N. Minlikeeva; Jo L. Freudenheim; Rikki Cannioto; Kevin H. Eng; J. Brian Szender; P.C. Mayor; John Lewis Etter; Daniel W. Cramer; Brenda Diergaarde; Jennifer A. Doherty; Thilo Dörk; Robert P. Edwards; Anna deFazio; Grace Friel; Marc T. Goodman; Peter Hillemanns; Estrid Høgdall; Allan Jensen; Susan J. Jordan; Beth Y. Karlan; Susanne K. Kjaer; Ruediger Klapdor; Keitaro Matsuo; Mika Mizuno; Christina M. Nagle; Kunle Odunsi; Lisa E. Paddock; Mary Anne Rossing; Joellen M. Schildkraut; Barbara Schmalfeldt

Background:Findings from in vitro studies suggest that increased exposure to thyroid hormones can influence progression of ovarian tumours. However, epidemiologic evidence on this topic is limited.Methods:We pooled data from 11 studies from the Ovarian Cancer Association Consortium. Using multivariate Cox proportional hazards models, we estimated associations between hyper- and hypothyroidism and medications prescribed for these conditions with 5-year all-cause survival among women diagnosed with invasive ovarian cancer.Results:Overall, there was a nonsignificant association with history of hyperthyroidism (n=160 cases) and mortality (HR=1.22; 95% CI=0.97–1.53). Furthermore, diagnosis of hyperthyroidism within the 5 years before ovarian cancer diagnosis was associated with an increased risk of death (HR=1.94; 95% CI=1.19–3.18). A more modest association was observed with history of hypothyroidism (n=624 cases) and mortality (HR=1.16; 95% CI=1.03–1.31). Neither duration of hypothyroidism nor use of thyroid medications was associated with survival.Conclusions:In this large study of women with ovarian cancer, we found that recent history of hyperthyroidism and overall history of hypothyroidism were associated with worse 5-year survival.


Journal of Lower Genital Tract Disease | 2016

Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study.

J.B. Szender; Rikki Cannioto; Nicolas R. Gulati; Kristina Schmitt; Grace Friel; Albina N. Minlikeeva; A. Platek; Emily H. Gower; Ryan Nagy; Edgar Khachatryan; P.C. Mayor; Karin A. Kasza; Shashikant Lele; Kunle Odunsi; Kirsten B. Moysich

Objective In this study, we investigated whether physical inactivity was associated with risk of cervical cancer in women treated at an American cancer hospital. Methods This case-control study included 128 patients with cervical cancer and 512 controls matched on age. Controls were women suspected of having but not ultimately diagnosed with a neoplasm. Physical inactivity was defined in accordance with the 2008 Physical Activity Guidelines for Americans. Thus, participants reporting, on average, no moderate or vigorous recreational physical activity were classified as inactive. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Results Compared with noncancer controls, those with cervical cancer had significantly increased odds of reporting abstinence from recreational physical activity (OR, 2.43; 95% CI, 1.56–3.80). No association was noted between occupational-related physical inactivity and cervical cancer (OR, 0.88; 95% CI, 0.58–1.36). Conclusions Our findings suggest that abstinence from regular recreational physical activity is associated with increased odds of cervical cancer. To our knowledge, this is the first US-based study examining these associations. Given the 2008 Physical Activity Guidelines for Americans, this study has identified yet another potential public health benefit to regular physical activity. Further investigation is needed using a larger sample and prospectively collected data to characterize dose of activity to mitigate risk and the optimal window of susceptibility.


Cancer Epidemiology, Biomarkers & Prevention | 2017

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.

Albina N. Minlikeeva; Jo L. Freudenheim; Kevin H. Eng; Rikki Cannioto; Grace Friel; J. Brian Szender; Brahm H. Segal; Kunle Odunsi; P.C. Mayor; Brenda Diergaarde; Emese Zsiros; Linda E. Kelemen; Martin Köbel; Helen Steed; Anna deFazio; Susan J. Jordan; Peter A. Fasching; Matthias W. Beckmann; Harvey A. Risch; Mary Anne Rossing; Jennifer A. Doherty; Jenny Chang-Claude; Marc T. Goodman; Thilo Dörk; Robert P. Edwards; Francesmary Modugno; Roberta B. Ness; Keitaro Matsuo; Mika Mizuno; Beth Y. Karlan

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470–3. ©2017 AACR.


International Journal of Gynecological Cancer | 2017

The Association of Peripheral Blood Regulatory T-Cell Concentrations with Epithelial Ovarian Cancer: A Brief Report

Rikki Cannioto; Lara E. Sucheston-Campbell; Shalaka S. Hampras; Ellen L. Goode; Keith L. Knutson; Roberta B. Ness; Francesmary Modugno; Paul K. Wallace; J. Brian Szender; P.C. Mayor; Chi Chen Hong; Janine M. Joseph; Grace Friel; Warren Davis; Mary Nesline; Kevin H. Eng; Robert P. Edwards; Bridget Kruszka; Kristina Schmitt; Kunle Odunsi; Kirsten B. Moysich

Objective There is a mounting body of evidence demonstrating higher percentages of regulatory T (Treg) cells in the peripheral blood of patients with cancer in comparison to healthy controls, but there is a paucity of epidemiological literature characterizing circulating Treg cells among patients with epithelial ovarian cancer (EOC). To investigate the role of peripheral Treg cells in ovarian neoplasms, we conducted a case–control study to characterize circulating concentrations of Treg cells among patients with EOC, women with benign ovarian conditions, and healthy controls without a history of cancer. Materials and Methods Participants were identified for inclusion due to their participation in the Data Bank and BioRepository program at Roswell Park Cancer Institute in Buffalo, NY. Patients included 71 women with a primary diagnosis of EOC and 195 women with a diagnosis of benign ovarian conditions. Controls included 101 age- and race-matched women without a history of cancer. Nonfasting, pretreatment peripheral blood levels of CD3+CD4+CD25+FOXP3+ Treg cells were measured using flow cytometric analyses and expressed as a percentage of total CD3+ cells and as a percentage of total CD3+CD4+ cells. Results Compared to healthy controls and women with benign ovarian conditions, patients with EOC had significantly higher frequency of Treg cells (P < 0.04). In multivariable logistic regression analyses using Treg frequency expressed as a percentage of CD+3 cells, we observed a significant positive association between Treg cell percentage and EOC risk, with each 1% increase associated with a 37% increased risk of EOC (odds ratio, 1.37; 95% confidence interval, 1.04–1.80). We observed a similar trend when Treg frequency was expressed as a percentage of CD3+CD+4 cells (odds ratio, 1.22; 95% confidence interval, 0.99–1.49). Conclusions The current study provides support that peripheral Treg cell frequency is elevated in patients with EOC in comparison to women with benign ovarian conditions and healthy controls.


Gynecologic Oncology | 2014

Aspirin and acetaminophen decrease the risk of cervical cancer in long-term users

C. Liu; Grace Friel; Nonna Kolomeyevskaya; S.B. Lele; Kunle Odunsi; Kirsten B. Moysich

Collaboration


Dive into the Grace Friel's collaboration.

Top Co-Authors

Avatar

Kunle Odunsi

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Rikki Cannioto

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Albina N. Minlikeeva

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

J. Brian Szender

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Kevin H. Eng

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Kirsten B. Moysich

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

P.C. Mayor

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge